Please login to the form below
Pruritus
This page shows the latest Pruritus news and features for those working in and with pharma, biotech and healthcare.
European Commission approves potential new treatment for Pompe disease
The most frequently reported adverse drug reactions (ADRs) (> 5%) were pruritus (9.4%), rash (8%), headache (7.2%), urticaria (6.5%), fatigue (6.5%), nausea (5.8%) and chills (5.1%).
Latest news
-
Menlo slumps as itching drug fails mid-stage trial
Menlo Therapeutics has said its phase 2 trial of serlopitant in chronic itching (pruritus) is a bust, blaming the result on a high placebo response rate. ... It also said the data has no read-through to its lead indication for serlopitant in pruritus
-
FDA delays decision on Intercept's NASH drug by three months
The safety and tolerability profile of obeticholic acid, which is associated with pruritus, may limit the number of patients and physicians who want to use the drug, even if it is
-
Gilead's NASH drug fails again
However, the results were far from a home run, as Ocaliva missed a co-primary endpoint of resolving NASH, and more than half of patients on the 25mg dose experience pruritus
-
Genfit claims FDA breakthrough status for liver disease drug
pruritus (itching).
-
Intercept builds its case for Ocaliva in NASH, but safety still an issue
The mixed efficacy data, coupled with safety results revealing that more than half of patients on the 25mg dose experienced itching (pruritus) that in 9% was sufficiently severe for them to
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
Cara Therapeutics put two questionnaires about itching at the centre of its phase 3 pruritus trial.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Creabilis names Catherine Moukheibir as chairman of the board
Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Body image and mental health: The psoriasis connection
4. Reich A, et al. Pruritus is an important factor negatively influencing the well-being of psoriatic patients.Acta dermato-venereologica, 2010; 90(3): 257-263.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
PMHub
Market Access Transformation
Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
